EquiReason

EquiReason research coverage

Haemonetics Corporation HAE

Healthcare · Medical Devices

24quarters analysed
12SEC filings read
2segments identified
13institutional managers tracked

Segments it reports

The business segments Haemonetics Corporation reports in its own SEC filings.

  • Hospital
  • Plasma
  • Blood Center

Product lines it reports

The product and service lines Haemonetics Corporation breaks its revenue into.

  • Hospital Products and Services
  • Plasma Products and Services
  • Blood Center Products and Services

Where its revenue is reported

The geographies Haemonetics Corporation reports revenue for. How much comes from each is in the product.

  • United States
  • Europe
  • Asia
  • Japan
  • Other Countryor Region

What we read

The sources behind this company, and how many records of each we hold.

  • Financial statements26
  • Quarterly metric series12
  • Business segments2
  • SEC filings12
  • Insider transactions (Form 4)6
  • Institutional positions (13F)7
  • Earnings events1
  • Earnings quality checks6
  • Estimate revisions11
  • GAAP vs non-GAAP reconciliation1
  • Seasonal pattern6
  • Multi-period trajectory7
  • Inflection detection1
  • Fiscal calendar1
  • Index membership4

What we look for

Every company is run through the same checks. Both answers are reported — a signal we looked for and did not find is as much a fact as one we did.

  • Revenue series24
  • Margin series6
  • Cash flow series24
  • Earnings series24
  • Per-share series3
  • Operating cash flow series24
  • Guidance changesnot found

This page says how much of Haemonetics Corporation we have read. What any of it means — the direction, the dates, the evidence and what would overturn it — is inside the product.

Open HAE in EquiReason

This page publishes coverage counts and reported breakdown names, but no financial figures, price data, rankings or investment conclusions. Sources are SEC filings, earnings calls and public institutional disclosures. How the research is made · All companies

Haemonetics Corporation (HAE) — research coverage | EquiReason